Amolyt Pharma
Amolyt Pharma's Overview
Amolyt Pharma is a global, clinical-stage biotechnology company dedicated to developing and delivering innovative therapeutic peptides for rare endocrine and related diseases. Their primary focus is on addressing significant unmet medical needs in conditions such as hypoparathyroidism with their lead candidate eneboparatide (AZP-3601), and acromegaly with AZP-3813. The company aims to improve patient outcomes and quality of life through targeted scientific advancements. In March 2024, AstraZeneca announced an agreement to acquire Amolyt Pharma, intending to integrate it into Alexion, AstraZeneca's rare disease group.
Where is Amolyt Pharma's Headquarters?
HQ Function
Serves as the primary operational and research hub, overseeing European clinical development, R&D activities, and corporate functions.
Notable Features:
Located within the Hôpital Edouard Herriot campus, specifically in 'Bâtiment Adénine – Recherche', suggesting a strong emphasis on research and close ties to clinical environments and medical expertise.
Work Culture:
Characterized by a science-driven, innovative, and collaborative atmosphere typical of biotech firms. There's a strong focus on addressing patient needs in rare diseases, fostering a mission-oriented environment.
HQ Significance:
Lyon offers a robust biotech ecosystem, providing access to skilled talent, research collaborations, and clinical infrastructure vital for Amolyt Pharma's drug development programs.
Values Reflected in HQ: The headquarters' location within a hospital's research building reflects Amolyt Pharma's commitment to patient-centric research, scientific excellence, and collaboration within the medical and scientific community.
Location:
Amolyt Pharma operates with an international scope, conducting clinical trials across multiple countries. Its physical presence is anchored by its headquarters in Lyon, France, and a key office in Cambridge, MA, USA. These locations support global functions including research and development, clinical operations, regulatory affairs, and strategic partnerships, aiming to deliver therapies for rare endocrine diseases to patients worldwide.
Street Address:
Hôpital Edouard Herriot, Bâtiment Adénine – Recherche, Place d’Arsonval
City:
Lyon
State/Province:
Auvergne-Rhône-Alpes
Country:
France
Amolyt Pharma's Global Presence
Cambridge, Massachusetts, USA
Address: One Kendall Square, Building 1400E, Suite 14-205, Cambridge, MA 02139, USA
To advance Amolyt Pharma's clinical programs in the U.S., manage engagement with regulatory bodies such as the FDA, and leverage the rich ecosystem of talent, investment, and scientific innovation in the Boston/Cambridge area.
Buying Intent Signals for Amolyt Pharma
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Amolyt Pharma
As of April 2025, Amolyt Pharma' leadership includes:
Investors of Amolyt Pharma
Amolyt Pharma has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
The most significant development concerning Amolyt Pharma's leadership and corporate structure in the last 12 months is the announcement in March 2024 of its pending acquisition by AstraZeneca. This event is expected to lead to the integration of Amolyt Pharma into AstraZeneca's rare disease unit, Alexion, which will likely influence future leadership roles. Prior to this major announcement, there were no widely publicized, distinct new hires or departures at the executive C-suite or SVP level within the preceding 12-month period.
Technology (Tech Stack) used by Amolyt Pharma
Discover the tools Amolyt Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Amolyt Pharma Email Formats and Examples
Amolyt Pharma likely utilizes standard corporate email address formats. Common patterns for companies in the biopharmaceutical industry include combinations of first name, last name, or initials at their domain amolytpharma.com.
[first_initial][last]@amolytpharma.com (e.g., jdoe@amolytpharma.com) or [first].[last]@amolytpharma.com (e.g., jane.doe@amolytpharma.com)
Format
t.abribat@amolytpharma.com
Example
80%
Success rate
News and media
AstraZeneca • March 14, 2024
AstraZeneca to acquire Amolyt Pharma
AstraZeneca has entered into a definitive agreement to acquire Amolyt Pharma, enhancing its rare disease portfolio, Alexion, with Amolyt's promising pipeline including eneboparatide (AZP-3601) for hypoparathyroidism. The proposed acquisition includes an upfront payment of $800 million, plus a contingent payment of $250 million....more
Amolyt Pharma • November 2, 2023
Amolyt Pharma Announces Positive Results from Phase 2b Trial of Eneboparatide for Hypoparathyroidism
Amolyt Pharma reported positive topline data from its CALYPSO Phase 2b trial of eneboparatide (AZP-3601) in hypoparathyroidism. The study met its primary endpoint, demonstrating potential to normalize calcium levels and reduce dependence on conventional therapy, supporting progression to Phase 3....more
Amolyt Pharma • June 27, 2023
Amolyt Pharma Receives FDA Fast Track Designation for Eneboparatide (AZP-3601)
The U.S. Food and Drug Administration (FDA) granted Fast Track designation to eneboparatide (AZP-3601) for the treatment of hypoparathyroidism. This designation aims to facilitate development and expedite review of therapies for serious conditions with unmet medical needs....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Amolyt Pharma, are just a search away.